Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PROCEPT BioRobotics ( (PRCT) ) has shared an announcement.
On July 23, 2025, PROCEPT BioRobotics announced the appointment of Larry L. Wood as President and CEO, effective September 2, 2025, succeeding Dr. Reza Zadno, who will retire on September 1, 2025. Dr. Zadno will transition to a consulting role, having led the company through significant growth, including the adoption of Aquablation therapy and a successful public offering. Mr. Wood, with over 40 years of experience in the medical technology industry, joins from Edwards Lifesciences and has been a member of PROCEPT BioRobotics’ board since 2024. The company also pre-announced second-quarter 2025 revenue of approximately $79.2 million, representing an annual growth of 48%.
The most recent analyst rating on (PRCT) stock is a Buy with a $99.00 price target. To see the full list of analyst forecasts on PROCEPT BioRobotics stock, see the PRCT Stock Forecast page.
Spark’s Take on PRCT Stock
According to Spark, TipRanks’ AI Analyst, PRCT is a Neutral.
The overall stock score reflects strong revenue growth and strategic advancements but is constrained by ongoing profitability and cash flow challenges. Technical indicators suggest a neutral stance, while valuation remains a concern due to negative earnings. The company’s strategic engagements and presentations at conferences offer some positive momentum.
To see Spark’s full report on PRCT stock, click here.
More about PROCEPT BioRobotics
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company manufactures the AQUABEAM and HYDROS Robotic Systems, with the latter being the only AI-powered robotic technology that delivers Aquablation therapy. This therapy is designed to provide effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia (BPH), a common prostate disease affecting approximately 40 million men in the United States. PROCEPT BioRobotics has established a significant body of clinical evidence supporting the benefits of Aquablation therapy.
Average Trading Volume: 840,032
Technical Sentiment Signal: Sell
Current Market Cap: $3.24B
For an in-depth examination of PRCT stock, go to TipRanks’ Overview page.